The COVID-19 pandemic has broadly disrupted biomedical treatment and research including non-invasive brain stimulation (NIBS). Moreover, the rapid onset of societal disruption and evolving regulatory restrictions may not have allowed for systematic planning of how clinical andresearch work may continue throughout the pandemic or be restarted as restrictions are abated. Theurgency to provide and develop NIBS as an intervention for diverse neurological and mental healthindications, and as a catalyst of fundamental brain research, is not dampened by the parallel efforts toaddress the most life-threatening aspects of COVID-19; rather in many cases the need for NIBS isheightened including the potential to mitigate mental health consequences related to COVID-19.

For more information click here.